EMERGENT BIOSOLUTIONS INC. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$149M↓-23.6%
2025-09-30$231M↓-21.3%$51M↓-55.4%33.1%
2025-06-30$141M↓-44.7%$-12M↑+95.8%1.1%
2025-03-31$222M↓-26.0%$68M↑+655.6%22.5%
2024-12-31$195M↓-29.6%
2024-09-30$294M↑+8.6%$115M↑+143.6%22.0%
2024-06-30$255M↓-24.6%$-283M↓-8.3%-79.9%
2024-03-31$300M↑+82.8%$9M↑+104.8%13.2%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$149M
↓-23.6% -$46M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 63 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+22.6pts
54.9%
Operating Margin↑+11.1pts
33.1%
Net Margin↓-16.9pts
22.2%

Go deeper